Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Inexpensive Urine Test Detects Prostate Cancer

By LabMedica International staff writers
Posted on 03 Jun 2013
An inexpensive, accurate way to detect prostate cancer could facilitate commercially available, at-home or point-of-care urine tests.

The sensitive detection of cancer biomarkers in urine could revolutionize cancer diagnosis and treatment, but such detectors must be low-cost, easy to interpret, and sensitive.

Chemists at the University of California (Irvine, CA, USA) have created a way to clearly identify clinically usable markers for prostate cancer in urine, meaning that the disease could be detected far sooner, with greater accuracy and at dramatically lower cost. More...
The same technology could potentially be used for bladder and multiple myeloma cancers, which also shed identifiable markers in urine.

Salt in urine helps conduct electricity but also makes it challenging for typical biosensors to differentiate the signals of cancer molecules from the background noise around them in the electrodes. The team developed a new type of sensor by adding nanoscale protein receptors to tiny, pencil-like viruses called bacteriophages (phages) that live only within bacteria. Double wrapping the phages with additional receptors greatly increases the capture and transmission of cancer molecule signals.

The chemists constructed a bioaffinity matrix of viruses integrated into Poly(3,4-ethylenedioxythiophene) (PEDOT) films for electrochemical sensing of a prostate cancer biomarker called prostate-specific membrane antigen (PSMA). High sensitivity to PSMA resulted from synergistic action by two different ligands to PSMA on the same phage particle. One ligand was genetically encoded, and the secondary recognition ligand was chemically synthesized to wrap around the phage. The team were able to detect subnanomolar quantities of PSMA in synthetic urine solution by using the synergistic, dual-ligand phage.

Reginald M. Penner, PhD, a professor of chemistry and the study's corresponding author, said, “Our goal is a device the size of a home pregnancy test priced around USD 10. You would buy it at the drugstore or the grocery store and test yourself. We're on the verge of a very important breakthrough in a new era of personal health management. The manufacturing costs would be low, because the material costs are very, very low. The receptors for recognizing the cancer markers are really inexpensive to make. That's why we chose these viruses. The receptors are also incredibly tough. They don't need to be refrigerated and can withstand nearly boiling temperatures, meaning the portable tests could be used in myriad weather conditions and storage situations." The study was published on April 24, 2013, in the Journal of the American Chemical Society.

Related Links:

University of California



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.